Annette Gilchrist: Native Cell Systems, Biased Agonism, and the Pharmacogenomics Gap

Biased agonism promised a cleaner path to better drugs - compounds that activate the beneficial arm of a receptor while leaving the harmful one alone. In practice, the picture is far more complicated. Whether a 20% reduction in beta-arrestin coupling matters therapeutically depends on the cell type, the complement of intracellular effectors present, and the receptor's own baseline activity in that tissue. These are questions you cannot answer in a HEK cell overexpressing a receptor it was never meant to see.

Annette Gilchrist has built her research program around that premise. Working on chemokine receptor CCR1 in multiple myeloma, free fatty acid receptor FFA2 in type 2 diabetes, and muscarinic receptors, her lab screens in disease-relevant cell lines and looks early for signaling bias - not as a theoretical exercise, but as a practical filter on what a compound might actually do in a patient.

That discipline led to a finding her field had not documented before: constitutive beta-arrestin activity at a wild-type FFA2 receptor, suppressible by an inverse agonist that then redirects signaling toward GQ coupling. For Gilchrist, the result was not a surprise so much as a confirmation - if you look in the right system, receptors show you things overexpression models never could.

ABOUT THE GUEST

Annette Gilchrist is Associate Professor of Pharmaceutical Sciences at Midwestern University, where her research focuses on GPCR signaling in disease-relevant contexts. Her lab studies chemokine receptor CCR1 in multiple myeloma and cancer-to-bone metastasis, free fatty acid receptor FFA2 in type 2 diabetes, and muscarinic M2 and M3 receptors, consistently prioritizing native and disease-proximal cell systems for screening. Before returning to academia, she co-founded two GPCR-focused biotechs with Heidi Hamm - CUE Biotech and Caden Biosciences - developing G-protein C-terminal mini-gene peptide tools that became widely adopted across the field. She also brings early industry experience from Pfizer, where her first sustained encounter with pharmacology as a discipline shaped how she has thought about the relationship between target validation and drug development ever since.

SCIENTIFIC THEMES OF THE CONVERSATION

• The native cell argument - why overexpression models produce systematically misleading screening data and what disease-relevant cell lines reveal instead
  

• The practical limits of biased agonism - cell-type context, effector availability, and why the G-protein vs. beta-arrestin framing rarely holds at the clinical level
  

• Constitutive beta-arrestin activity and inverse agonism - a first-in-kind finding at wild-type FFA2 and its implications for biased ligand campaign design
  

• GPCR pharmacogenomics - natural receptor variation, interpatient drug response differences, and a largely unexplored opportunity in existing drug pipelines
  

• Antibody therapeutics for GPCRs - the pipeline case, the approval rate argument, and why orphan receptor targeting may not require knowing the endogenous ligand
  

• Receptor dimerization - BRET biosensors, what we still do not know about physiological relevance, and why the tools are finally beginning to close the gap

KEY INSIGHTS FROM THE CONVERSATION

The cell you screen in determines the biology you can find

Running a GPCR screen in a HEK cell overexpression model removes the intracellular proteins a receptor actually encounters in disease tissue - effectors like Go or Gz that are critical in neuronal signaling, for example, and simply absent in standard lines. Gilchrist has argued for disease-relevant cell systems for over 15 years, and her lab's discovery of constitutive beta-arrestin activity at FFA2 is a direct product of that discipline - a result that would have been invisible in a standard overexpression model.

Biased agonism is context-dependent, not receptor-intrinsic

The field has treated biased agonism largely as a property of a compound and a receptor. Gilchrist's argument is that it is also a property of the cell. The same compound may produce a functionally meaningful shift in one cell type and a negligible one in another, depending on the G-protein isoforms present, the receptor conformation in that membrane environment, and what other proteins are competing for the same intracellular space. How much bias is enough is not a pharmacological question with a single answer.

An inverse agonist where none had been reported - constitutive beta-arrestin coupling at FFA2

Gilchrist's lab entered the FFA2 project looking for GQ-biased agonists to drive insulin release. What they found instead was that FFA2 appears to be constitutively coupled to beta-arrestin in the relevant cell system - and that an inverse agonist against that constitutive activity effectively redirects the receptor toward GQ coupling. It was a result that had been documented in a mutant vasopressin receptor but never in a normal wild-type receptor. The aha moment was not the result itself but recognizing what it meant for how you could design the campaign.

Pharmacogenomic variation in GPCRs may already be shaping clinical drug response - unacknowledged

A paper by Hauser mapped pharmacogenomic variation across the GPCR-ome and showed, among other findings, that many of the GPCRs carrying the highest mutation loads are hormone receptors - FSH, LH, and others implicated in fertility. Patients taking drugs that target GPCRs with natural population-level variants are almost certainly responding differently based on their receptor genetics. Almost no company with an approved GPCR-targeting drug has gone back to look at what common receptor variants do to their compound. Gilchrist believes they should.

The mini-gene origin: reading one paper, seeing the missing experiment

While a postdoc in Heidi Hamm's lab, Gilchrist read a paper describing how BARK C-terminal peptides had been inserted into a plasmid as tools. The question that followed was immediate: why hadn't anyone done the same with G-protein C-termini? The peptides she developed - 11 amino acids rather than 55, which created their own detection challenges - became widely used across the field for measuring receptor-G-protein interactions and screening for allosteric modulators. The insight was not a long deliberation. It was a single reading of someone else's work and a recognition that an obvious experiment had not yet been done.

Antibody therapeutics for GPCRs: the pipeline argument

Biologics have a substantially higher success rate than small molecules moving through the drug development pipeline. GPCRs are well-validated targets with known physiological relevance. The combination of those two facts, Gilchrist argues, makes antibody-based GPCR therapeutics an underexplored area - particularly for orphan GPCRs, where compounds are already being developed against receptors whose endogenous ligands remain unknown. The precedent of drugging a receptor without knowing what activates it naturally, and getting therapeutic results, suggests the field does not always need the full biology before it can act on the pharmacology.

The first screen: looking for antagonists, finding agonists instead

The principle that Gilchrist now teaches - follow the unexpected result, ask why it happened, do not repeat it away - came from her own first encounter with exactly that situation. Running a small-molecule screen in Heidi Hamm's lab, looking for compounds that would block G-protein binding, she found agonists: compounds that made the G-protein bind better, some of which trapped the receptor in a state where it could not signal further. It was not the experiment she had designed. The years of research that followed came directly from not dismissing it.

EPISODE TIMELINE

Timestamps are AI-generated from the transcript and may not reflect the final edited episode.

• 00:00 Introduction

• 02:18 Career trajectory - from medical school intent to Pfizer, PhD in immunology, and an accidental entry into GPCR biology

• 07:25 Entering GPCR research through Heidi Hamm's lab - and why the committee said G proteins had already won their Nobel Prize

• 12:39 Co-founding CUE Biotech and Caden Biosciences - allosteric modulator screens and G-protein C-terminal peptide tools

• 17:17 Current receptors: CCR1, FFA2, and muscarinic M2 and M3

• 19:28 CCR1 in multiple myeloma - osteoclast/osteoblast imbalance and the cancer-to-bone metastasis problem

• 23:01 Why native cell lines change what a screen can detect

• 27:53 The limits of biased agonism - effector context, cell-type dependence, and allosteric complexity

• 32:08 GPCR pharmacogenomics - variant receptors, the Hauser paper, and what industry has not yet done with existing drugs

• 39:43 BRET biosensors, receptor dimerization, and what remains unresolved about physiological relevance

• 42:00 Antibody therapeutics for GPCRs and the case for orphan receptor targeting

• 48:27 Two aha moments: the G-protein mini-gene origin and finding an inverse agonist where none had been reported

SELECTED QUOTES

About this episode

Originally, Annette wanted to be a medical doctor but as luck has it, she didn’t get into medical school when she first applied. Instead, she discovered research and started her Ph.D. the day she should have started medical school. Dr. Gilchrist completed her Ph.D. in Biomedical Sciences / Immunology at the University of Connecticut and went on to become a postdoctoral fellow at UIC (University of Illinois at Chicago). Annette worked in industry, academia and her entrepreneurial side led her to three companies, Cue Biotech, Caden Biosciences, and MyGenomeRx in addition to being a consultant for over a decade. Dr. Gilchrist is also an associate professor at the Department of Pharmaceutical Sciences.

Join me and learn more about Annette’s career, our common love for chemokines, and how you can use your training as a scientist in so many different ways.

Dr. Annette Gilchrist on the web

• LinkedIn

• Midwestern University

• Google Scholar

• Pubmed

• Twitter

• Research Gate

• Dr. GPCR Ecosystem